Browse by author
Lookup NU author(s): Dr Rob DudleyORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2022 The AuthorsBackground: The social withdrawal of many patients with psychosis can be conceptualised as agoraphobic avoidance due to a range of long-standing fears. We hypothesised that greater severity of agoraphobic avoidance is associated with higher levels of psychiatric symptoms and lower levels of quality of life. We also hypothesised that patients with severe agoraphobic avoidance would experience a range of benefits from an automated virtual reality (VR) therapy that allows them to practise everyday anxiety-provoking situations in simulated environments. Methods: 345 patients with psychosis in a randomised controlled trial were categorised into average, moderate, high, and severe avoidance groups using the Oxford Agoraphobic Avoidance Scale. Associations of agoraphobia severity with symptom and functioning variables, and response over six months to brief automated VR therapy (gameChange), were tested. Results: Greater severity of agoraphobic avoidance was associated with higher levels of persecutory ideation, auditory hallucinations, depression, hopelessness, and threat cognitions, and lower levels of meaningful activity, quality of life, and perceptions of recovery. Patients with severe agoraphobia showed the greatest benefits with gameChange VR therapy, with significant improvements at end of treatment in agoraphobic avoidance, agoraphobic distress, ideas of reference, persecutory ideation, paranoia worries, recovering quality of life, and perceived recovery, but no significant improvements in depression, suicidal ideation, or health-related quality of life. Conclusions: Patients with psychosis with severe agoraphobic avoidance, such as being unable to leave the home, have high clinical need. Automated VR therapy can deliver clinical improvement in agoraphobia for these patients, leading to a number of wider benefits.
Author(s): Freeman D, Lambe S, Galal U, Yu L-M, Kabir T, Petit A, Rosebrock L, Dudley R, Chapman K, Morrison A, O'Regan E, Murphy E, Aynsworth C, Jones J, Powling R, Grabey J, Rovira A, Freeman J, Clark DM, Waite F
Publication type: Article
Publication status: Published
Journal: Schizophrenia Research
Year: 2022
Volume: 250
Pages: 50-59
Print publication date: 01/12/2022
Acceptance date: 27/10/2022
Date deposited: 26/06/2023
ISSN (print): 0920-9964
ISSN (electronic): 1573-2509
Publisher: Elsevier B.V.
URL: https://doi.org/10.1016/j.schres.2022.10.008
DOI: 10.1016/j.schres.2022.10.008
Altmetrics provided by Altmetric
